TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7669466

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rocuronium combined with Vecuronium, Pipecuronium, or Pancuronium
Number of subjects: 200
Study: 1955546

Group type: COMPARATOR
Intervention: Follicle aspiration only (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follicle aspiration and flushing with 10 ml of flushing medium (Group 2)
Number of subjects: 0
Study: 7304485

Group type: EXPERIMENTAL
Intervention: Guar gum (9.0 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (glucose in 600 mg capsules)
Number of subjects: 24
Study: 31830211

Group type: EXPERIMENTAL
Intervention: Enzalutamide, 160 mg once daily
Number of subjects: 1672
Study: 30537138

Group type: EXPERIMENTAL
Intervention: Intensified BP group (INTENS, target 24-hour MAP <50th percentile, n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard BP group (STAND, target 24-hour MAP 50-95th percentile, n=11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intensified BP group (INTENS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard BP group (STAND)
Number of subjects: 23
Study: 28605263

Group type: EXPERIMENTAL
Intervention: High-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks (20 two-minute breaks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prolonged sitting (20 two-minute sedentary computer game breaks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline PAEE
Number of subjects: 33
Study: 26578734

Group type: EXPERIMENTAL
Intervention: Intensive surveillance
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Minimal surveillance
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1228
Study: 25208030

Group type: EXPERIMENTAL
Intervention: Novel guidewire (270-cm, hyperflexible, hydrophilic tip with stiff shaft)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard group (260-cm long, angled-tip hydrophilic wire with nitinol wire as needed)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Novel guidewire
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 197
Study: 23021480

Group type: EXPERIMENTAL
Intervention: Parent-delivered Early Start Denver model (P-ESDM) intervention (1-hour/week for 12 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Community treatment as usual
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (P-ESDM and community treatment)
Number of subjects: 98
Study: 20193938

Group type: EXPERIMENTAL
Intervention: Peer review evaluation system
Number of subjects: 46
Study: 17265052

Group type: EXPERIMENTAL
Intervention: Second MRI after preoperative radiotherapy
Number of subjects: 25
Study: 15877041

Group type: EXPERIMENTAL
Intervention: Computer-aided learning (CAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAL programs
Number of subjects: 0
Study: 11564356

Group type: EXPERIMENTAL
Intervention: Telepharmacy counseling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (written instructions)
Number of subjects: 36
Study: 9780534

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bassini repair
Number of subjects: 0
Study: 8163050

Group type: EXPERIMENTAL
Intervention: Amylin infusion for 6 hours during postabsorptive and euglycaemic hyperinsulinaemic clamp phases.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control infusion (placebo) for 6 hours during postabsorptive and euglycaemic hyperinsulinaemic clamp phases.
Number of subjects: 7
Study: 3139279

Group type: EXPERIMENTAL
Intervention: diethylstilbestrol (DES) or bilateral orchiectomy
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: leutinizing hormone‐releasing hormone (LHRH) analog buserelin
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: methotrexate plus DES or orchiectomy
Number of subjects: 265
Study: 30507710

Group type: EXPERIMENTAL
Intervention: LMWH followed by rivaroxaban
Number of subjects: 118

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 118
Study: 28097324

Group type: EXPERIMENTAL
Intervention: NRG-GBM-RPA model incorporating MGMT protein, c-Met protein, and clinical variables
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: MGMT protein expression
Number of subjects: 452

Group type: COMPARATOR
Intervention: MGMT promoter methylation
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Single-marker analysis of protein biomarkers (MGMT, survivin, c-Met, pmTOR, Ki-67)
Number of subjects: 452
Study: 25446068

Group type: EXPERIMENTAL
Intervention: Favorable position
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unfavorable position
Number of subjects: 18
Study: 23160037

Group type: EXPERIMENTAL
Intervention: Strontium acetate/silica toothpaste
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Arginine/calcium carbonate paste
Number of subjects: 80
Study: 21098692

Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone 16 mg in the fasted state
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone 16 mg after a high-fat breakfast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate-release hydromorphone 16 mg daily dose (4 mg qid) in the fasted state
Number of subjects: 30
Study: 19408811

Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (150 mmol/L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoride dentifrice (1030 ppm)
Number of subjects: 10
Study: 17696669

Group type: EXPERIMENTAL
Intervention: ABLE screening tool
Number of subjects: 5972
Study: 15768834

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11403725

Group type: EXPERIMENTAL
Intervention: New point-of-care test for smoking
Number of subjects: 187
Study: 9355212

Group type: EXPERIMENTAL
Intervention: 2 days of recommended bed rest
Number of subjects: 203

Group type: COMPARATOR
Intervention: 7 days of recommended bed rest
Number of subjects: 203
Study: 8453432

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tranylcypromine and Amitriptyline combined
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 3513009

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unchanged conventional treatment
Number of subjects: 36
Study: 31334768

Group type: EXPERIMENTAL
Intervention: Eighth edition AJCC/UICC staging system with integrated plasma EBV DNA
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Integration of pretreatment EBV values (<2300 vs ≥2300 copies/ml)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Seventh edition AJCC/UICC staging system
Number of subjects: 205
Study: 29882276

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO; 40,000 IU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 44
Study: 25758941

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation during hospitalization and for up to four weeks after discharge
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard care treatment and rehabilitation following usual guidelines for the treatment of stroke patients
Number of subjects: 71
Study: 24392772

Group type: EXPERIMENTAL
Intervention: Creatine supplementation before resistance training (0.1g*kg(‐1) creatine before + 0.1g*kg(‐1) placebo after RT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo before resistance training + creatine after resistance training
Number of subjects: 22
Study: 23390778

Group type: EXPERIMENTAL
Intervention: Original clopidogrel 600 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Generic clopidogrel 600 mg
Number of subjects: 49
Study: 20039319

Group type: EXPERIMENTAL
Intervention: Genetic variation in IGFBP1 (rs35539615)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Genetic variation in IGFBP3 (rs2453839)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Genetic variation in IGF1 (rs35767)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Ethnicity stratification for IGFBP3 SNPs
Number of subjects: 819
Study: 18284648

Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renzapride 1 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg/day (women)
Number of subjects: 0
Study: 15625258

Group type: EXPERIMENTAL
Intervention: General anesthesia plus nerve stimulator guided pudendal nerve block
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia alone or in combination with placebo blocks
Number of subjects: 90
Study: 12895220

Group type: EXPERIMENTAL
Intervention: Quadruple therapy with tetracycline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole (with metronidazole resistance)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadruple therapy with metronidazole (without metronidazole resistance)
Number of subjects: 100
Study: 10225073

Group type: EXPERIMENTAL
Intervention: Single-shot spinal anaesthesia (SS) with 17.5 mg bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous spinal analgesia (CSA) starting with 5 mg bupivacaine and incremental doses of 2.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative assessment
Number of subjects: 60
Study: 8931786

Group type: EXPERIMENTAL
Intervention: Ganciclovir induction therapy for 21 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High CMV load at presentation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High CMV load in blood
Number of subjects: 45
Study: 8351363

Group type: EXPERIMENTAL
Intervention: Forced infusion (FI) of urokinase (UK)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional slow continuous infusion (CI) of urokinase (UK)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lytic therapy (both FI and CI)
Number of subjects: 25
Study: 2875479

Group type: EXPERIMENTAL
Intervention: Benzo-pyrone (Paroven/Venoruton, Zyma)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30265093

Group type: EXPERIMENTAL
Intervention: Nonadiabatic holonomic single-qubit quantum gates on transmon qubit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonadiabatic holonomic single-qubit quantum gates on microwave cavity
Number of subjects: 0
Study: 27144837

Group type: EXPERIMENTAL
Intervention: 10 minutes of direct vibration (0-170 Hz)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 11
Study: 23302490

Group type: EXPERIMENTAL
Intervention: Biotin deficiency
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biotin sufficiency
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biotin supplementation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biotin transporters and carboxylases
Number of subjects: 16
Study: 22072347

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy + acupressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Information session
Number of subjects: 40
Study: 19266381

Group type: EXPERIMENTAL
Intervention: Viagra plus sex therapy (VST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viagra-only (VO)
Number of subjects: 0
Study: 17570832

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: EQ-5D+C
Number of subjects: 196
Study: 15454133

Group type: EXPERIMENTAL
Intervention: Telerounding (one afternoon telerounding visit)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Robotic telerounding (substitution of one daily bedside round with a robotic telerounding visit)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard once-daily attending bedside rounds
Number of subjects: 85
Study: 11432326

Group type: EXPERIMENTAL
Intervention: Flonivin BS (Bacillus Subtilis IP 5832), 3 x 2 capsules daily for 7 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Flonivin BS (Bacillus Subtilis IP 5832)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9209778

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 10
Study: 8218619

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 3696303

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for three consecutive days, once every two weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 82
Study: 29778403

Group type: EXPERIMENTAL
Intervention: Sputum induction
Number of subjects: 124
Study: 27438322

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 23926058

Group type: EXPERIMENTAL
Intervention: 200-600 mg TPD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 mg linezolid twice/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TPD with food
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TPD or tedizolid phosphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22285055

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin syrup (90 mg/kg per day in two doses for 5 days)
Number of subjects: 4410

Group type: COMPARATOR
Intervention: Oral co-trimoxazole (one dose) and referral for admission and intravenous antibiotics
Number of subjects: 4410
Study: 19342110

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: AAIR pacing
Number of subjects: 60
Study: 18521899

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Doxorubicin alone
Number of subjects: 1953

Group type: EXPERIMENTAL
Intervention: Doxorubicin combined with ifosfamide
Number of subjects: 1953
Study: 17092415

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 33
Study: 12679215

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (Black patients)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (Black patients)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo (Black patients)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (White patients)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (White patients)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo (White patients)
Number of subjects: 551
Study: 11263532

Group type: COMPARATOR
Intervention: No stimulation (group I)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Recombinant FSH 150 IU/day for 3 days (group II)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: IVM period of 28 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: IVM period of 36 hours
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cycles with an increase in oestradiol concentration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cycles without an increase in oestradiol concentration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cycles with an increase in inhibin A concentration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cycles without an increase in inhibin A concentration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Overall pregnancy rate per aspiration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Overall pregnancy rate per transfer
Number of subjects: 87
Study: 9023710

Group type: COMPARATOR
Intervention: Captopril therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril plus Tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perindopril therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibition in a subgroup of AMI patients
Number of subjects: 0
Study: 2035381

Group type: EXPERIMENTAL
Intervention: Bruce-Standing Recovery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abrupt Exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warm-Up Exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bruce-Supine Recovery
Number of subjects: 18
Study: 7049966

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 55
Study: 30787343

Group type: EXPERIMENTAL
Intervention: d[Ca] 1.75 mmol/L
Number of subjects: 19

Group type: COMPARATOR
Intervention: d[Ca] 1.25 mmol/L
Number of subjects: 19
Study: 28893387

Group type: EXPERIMENTAL
Intervention: Usual care + Pulsed Electromagnetic Frequency (PEMF) therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 25425475

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks (Q4W)
Number of subjects: 0
Study: 24535482

Group type: EXPERIMENTAL
Intervention: 13.5 mg hyperbaric bupivacaine with 2 mg preservative-free ketorolac
Number of subjects: 62

Group type: COMPARATOR
Intervention: 13.5 mg hyperbaric bupivacaine with spinal saline
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 22828593

Group type: EXPERIMENTAL
Intervention: Coordinated messages (brochures, posters) encouraging clinic attendance
Number of subjects: 21057
Study: 19176543

Group type: EXPERIMENTAL
Intervention: 10 mg asoprisnil daily for 12 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 25 mg asoprisnil daily for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17996657

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 15870415

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 302

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 302

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting list
Number of subjects: 302

Group type: COMPARATOR
Intervention: Acupuncture vs Sham acupuncture
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Proportion of responders
Number of subjects: 302
Study: 12473699

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 30
Study: 9674466

Group type: EXPERIMENTAL
Intervention: Flutter treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 14
Study: 8592286

Group type: EXPERIMENTAL
Intervention: Physical therapy and continuous passive motion (n = 21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physical therapy only (n = 18)
Number of subjects: 39
Study: 2228322

Group type: EXPERIMENTAL
Intervention: sulglycotide (oral, 200 mg t.i.d. for 6 weeks, n = 93)
Number of subjects: 187

Group type: COMPARATOR
Intervention: sucralfate (oral, 1 g t.i.d. for 6 weeks, n = 94)
Number of subjects: 187
Study: 346631

Group type: EXPERIMENTAL
Intervention: 50% lactulose syrup
Number of subjects: 47
Study: 31434528

Group type: EXPERIMENTAL
Intervention: Strategy-based cognitive training (n = 33)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Knowledge-based training (active control group, n = 31)
Number of subjects: 64
Study: 31586530

Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe combination (40/10 mg)
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1687
Study: 27899298

Group type: EXPERIMENTAL
Intervention: Menthol (0.1-500mM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhibition of NO, EDHFs, or sensory nerves
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4% menthol gel (0.017mL·cm‐2)
Number of subjects: 10
Study: 26497109

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterole (FF/VI) 200/25 μg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 μg
Number of subjects: 16
Study: 23621752

Group type: EXPERIMENTAL
Intervention: Intermediate-dose IFN
Number of subjects: 855

Group type: COMPARATOR
Intervention: High-dose IFN
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 855
Study: 22185647

Group type: EXPERIMENTAL
Intervention: Tailored counselling to decrease sitting time, focusing on commute and work time, reinforced during the first 6 months followed by a 6-month maintenance period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored counselling regarding leisure time to encourage family physical activities.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometer data collection from adults and children, fasting blood samples, diurnal heart rate variability, muscle activity measurements, fundamental motor skills assessment, and body composition measurements.
Number of subjects: 0
Study: 17614242

Group type: EXPERIMENTAL
Intervention: Brief family treatment (BFT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continuing care (regardless of treatment condition)
Number of subjects: 45